Highlands Oncology Group - Springdale

Summary

Highlands Oncology Group - Springdale is a medical facility located in Springdale, Arkansas. This center is recognized for care of Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer, Lung Cancer, Multiple Myeloma and other specialties. Highlands Oncology Group - Springdale is involved with conducting 6 clinical trials across 16 conditions. There are 1 research doctors associated with this hospital, such as Joseph T Beck.

Top PIs

Clinical Trials running at Highlands Oncology Group - Springdale

Non-Small Cell Lung Cancer

Multiple Myeloma

Cancer

Lung Cancer

Telisotuzumab Adizutecan

for Non-Small Cell Lung Cancer

Non-small cell lung cancer (NSCLC) is a common type of lung cancer where abnormal cells in the lungs grow out of control. The purpose of this study is to assess adverse events and change in disease activity of telisotuzumab adizutecan compared to standard of care (SOC). Telisotuzumab adizutecan is an investigational drug being developed for the treatment of NSCLC. This study will be divided into two stages, in the first stage (phase 2) participants will receive 1 of 2 doses of telisotuzumab adizutecan. In the second stage (phase 3) participants will receive the recommended phase 3 dose (RP3D) of telisotuzumab adizutecan, from the previous stage, or SOC. Approximately 430 adult participants with NSCLC will be enrolled in the study in 200 sites around the world. In phase 2, participants will receive 1 of 2 intravenous (IV) doses of telisotuzumab adizutecan. In phase 3, participants will receive the IV RP3D of telisotuzumab adizutecan, or SOC. The study will run for a duration of approximately 69 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.

Recruiting

1 award

Phase 2 & 3

6 criteria

Adagrasib + Pembrolizumab

for Lung Cancer

This trial tests two drugs, MRTX849 and pembrolizumab, in patients with advanced lung cancer who have a specific genetic mutation. MRTX849 targets the mutation to stop cancer growth, while pembrolizumab boosts the immune system to fight the cancer. The study aims to see how well these treatments work alone and together.

Recruiting

1 award

Phase 2 & 3

4 criteria